Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;99(4):827-832.
doi: 10.4269/ajtmh.17-0895.

Understanding the Liver-Stage Biology of Malaria Parasites: Insights to Enable and Accelerate the Development of a Highly Efficacious Vaccine

Affiliations

Understanding the Liver-Stage Biology of Malaria Parasites: Insights to Enable and Accelerate the Development of a Highly Efficacious Vaccine

Annie X Mo et al. Am J Trop Med Hyg. 2018 Oct.

Abstract

In August 2017, the National Institute of Allergy and Infectious Diseases convened a meeting, entitled "Understanding the Liver-Stage Biology of Malaria Parasites to Enable and Accelerate the Development of a Highly Efficacious Vaccine," to discuss the needs and strategies to develop a highly efficacious, whole organism-based vaccine targeting the liver stage of malaria parasites. It was concluded that attenuated sporozoite platforms have proven to be promising approaches, and that late-arresting sporozoites could potentially offer greater vaccine performance than early-arresting sporozoites against malaria. New knowledge and emerging technologies have made the development of late-arresting sporozoites feasible. Highly integrated approaches involving liver-stage research, "omics" studies, and cutting-edge genetic editing technologies, combined with in vitro culture systems or unique animal models, are needed to accelerate the discovery of candidates for a late-arresting, genetically attenuated parasite vaccine.

PubMed Disclaimer

References

    1. World Health Organization , 2017. WHO Global Vaccine Action Plan (GVAP) Available at: www.who.int/entity/immunization/global_vaccine_action_plan/web_gvap_secr.... Accessed July 30, 2018.
    1. World Health Organization , 2013. WHO Malaria Vaccine Technology Roadmap Available at: http://www.who.int/immunization/topics/malaria/vaccine_roadmap/en/. Accessed July 30, 2018.
    1. RTS,S Clinical Trials Partnership , 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 31–45. - PMC - PubMed
    1. Mendes AM, Scholzen A, Mueller AK, Khan SM, Sauerwain RW, Prudencio M, 2017. Whole organism pre-erythrocytic vaccines. Rodrgue A, Mota MM, eds. Malaria: Immune Response to Infection and Vaccination. Cham, Switzerland: Spinger International Publishing, 121–122.
    1. Seder RA, et al. VRC 312 Study Team , 2013. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341: 1359–1365. - PubMed

Publication types

MeSH terms

LinkOut - more resources